WKD Hellboy | 🏴󠁧󠁢󠁳󠁣󠁴󠁿🏳️‍🌈🇺🇦
LightNews LightNews
banner
wkdhellboy.bsky.social
WKD Hellboy | 🏴󠁧󠁢󠁳󠁣󠁴󠁿🏳️‍🌈🇺🇦
@wkdhellboy.bsky.social
72 followers 180 following 15 posts
I am who, I am, and I am not, who I am not. He/Him, They/Them, Gay, 24
Posts Replies Media Videos
Reposted by WKD Hellboy | 🏴󠁧󠁢󠁳󠁣󠁴󠁿🏳️‍🌈🇺🇦
culturecrave.co
Robot powered by Qualcomm’s new AI chip dies mid-presentation 😭
July 24, 2026 at 7:28 PM
wkdhellboy.bsky.social
@markhamillofficial.bsky.social

Hi Mark,

I’m rewatching Ep. IV with the family and a random question popped into my head that I was wondering if you might be able to help us with?
May 30, 2026 at 8:14 PM
Reposted by WKD Hellboy | 🏴󠁧󠁢󠁳󠁣󠁴󠁿🏳️‍🌈🇺🇦
mehdirhasan.bsky.social
From me, a list of Trump supporters who killed, or tried to kill, Democrats and opponents of Trump in recent years (since the right are now claiming all the political violence is from the left!)

Receipts:
zeteo.com/p/charlie-ki...
September 11, 2025 at 3:22 PM
Reposted by WKD Hellboy | 🏴󠁧󠁢󠁳󠁣󠁴󠁿🏳️‍🌈🇺🇦
hhesterm.bsky.social
I am horrified. If you use US material, download all old reports you use. The record will be erased. Even that might not save you: every report sourced from the US will now have to be suspected of politicised manipulation and will in the future the same credibility as Iran’s human rights reports
davidrvetter.bsky.social Dave Vetter @davidrvetter.bsky.social · Aug 8
The Trump administration has announced that the US will rewrite past climate reports, in a clear attempt to erase scientific history and undermine the consensus on human-caused climate change.
US to rewrite its past national climate reports
US President Donald Trump's administration is revising past editions of the nation's premier climate report -- its latest move to undermine the scientific consensus on human-caused global warming.
www.france24.com
August 8, 2025 at 8:37 AM
Reposted by WKD Hellboy | 🏴󠁧󠁢󠁳󠁣󠁴󠁿🏳️‍🌈🇺🇦
detetiive.bsky.social
pokémon logos i made
May 15, 2025 at 3:06 PM
wkdhellboy.bsky.social
Define “Beautiful”

The Tale of Princess Kaguya
May 9, 2025 at 7:21 PM
wkdhellboy.bsky.social
Watch Barbie come to life like never before!
April 14, 2025 at 7:06 AM
Reposted by WKD Hellboy | 🏴󠁧󠁢󠁳󠁣󠁴󠁿🏳️‍🌈🇺🇦
sailorrooscout.bsky.social
The study has been published in Nature. YES, it is PEER-REVIEWED.
• www.nature.com/articles/s41...

IMPORTANT THINGS TO NOTE ‼️
IMPORTANT THINGS TO NOTE !! • KEEP IN MIND THESE ARE RESULTS THAT HAVE HELD UP APPROXIMATELY THREE YEARS showing that benefits demonstrated years ago have held up over time. That is ASTOUNDING. • Researchers say the results of a Phase I trial of an therapeutic cancer vaccine aimed at preventing kidney cancer show promise. • This new study found that ALL patients with ADVANCED stage kidney cancer had successful anti-cancer immune responses AND have remained CANCER-FREE approximately THREE years after treatment. • The study, demonstrates the potential of personalized vaccines to change the course of certain cancer types, but larger, longer trials are needed to confirm this approach. • Cancer vaccines developed with different molecular recipes are still in their early stages, before strong conclusions can be made. • While the findings are encouraging, the vaccine is still in early testing and will likely take years before it becomes widely available. How personalized peptide cancer vaccines work Scientists identify neoantigens, abnormal proteins produced by cancer cells. They take a sample of the patient's mutated cancer cells. The neoantigens are used to create a vaccine tailored to the patient's tumor. The vaccine is administered, prompting the immune system to target the cancer cells with those proteins. The immune system's T-cells attack and destroy the tumor cells, shrinking the cancer. ABSTRACT Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens. However, whether such responses can target cancer driver mutations, lead to immune recognition of a patient's tumour and result in clinical activity are largely unknown. These questions are of particular interest for patients who have tumours with a low mutational burden. Here we conducted a phase l trial (ClinicalTrials.gov identifier NCTO2950766) to test a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage Ill or IV) with or without ipilimumab administered adjacent to the vaccine. At a median follow-up of 40.2 months after surgery, none of the 9 participants enrolled in the study had a recurrence of RCC. No dose-limiting toxicities were observed. All patients generated T-cell immune responses against the PCV antigens, including to RCC driver mutations in VHL, PBRM1, BAP1, KDM5C and PIK. Following vaccination, there was a durable expansion of peripheral T-cell clones. Moreover, T-cell reactivity against autologous tumours was detected in seven out of nine patients. Our results demonstrate that neoantigen-targeting PCVs in high-risk RCC are highly immunogenic, capable of targeting key driver mutations and can induce antitumour immunity. These observations, in conjunction with the absence of recurrence in all nine vaccinated patients, highlights the promise of PCVs as effective adjuvant therapy in RCC. This study involved a large and collaborative team across multiple institutions, with key leadership from co-senior authors Toni Choueiri, Derin Keskin, Patrick Ott, and Catherine Wu from DFCI. Research reported in this release was supported by the National Institutes of Health under award numbers 1R37CA279822-01 and P30CA016359. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The research was also funded by the Gateway for Cancer Research, U.S. Department of Defense, Louis Goodman and Alfred Gilman Yale Scholar Fund, Yale Cancer Center, Dana-Farber/ Harvard Cancer Center, Harvard Medical School, Trust Family Foundation, Michael Brigham, Pan Mass Challenge, Hinda L. and Arthur Marcus Foundation, The Loker Pinard Fund for Kidney Cancer Research at Dana-Farber Cancer Institute, and Conquer Cancer Foundation/Sontag Foundation.
February 26, 2025 at 5:02 PM
Reposted by WKD Hellboy | 🏴󠁧󠁢󠁳󠁣󠁴󠁿🏳️‍🌈🇺🇦
joncooper-us.bsky.social
An 11-year-old girl took her own life in Texas after she was tormented for weeks by her sixth-grade classmates at Gainesville Intermediate School, who threatened to call ICE authorities and have her family deported from the US, her grieving parents have said. 💔 💔
11-year-old took her own life over deportation threats, family says
‘I waited a whole week for a miracle that my daughter would be well, but unfortunately, nothing could be done,’ despaired her mother
www.independent.co.uk
February 19, 2025 at 11:06 PM